Case of anakinra as a steroid‐sparing agent for gout inflammation

Gratton, Sarah B.; Scalapino, Kenneth J.; Fye, Kenneth H.

doi:10.1002/art.24694

Cited by 44 publications

(14 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The utility of inhibiting IL-1 in gout was demonstrated in case reports 22,23,24 and clinical studies of rilonacept and other IL-1 inhibitors 25,26,27,28 . Recent studies with rilonacept further support the rationale for IL-1 as an appropriate therapeutic target for prevention of gout flares in patients initiating ULT 27,28,29 .…”

Section: Journal Of Rheumatologymentioning

confidence: 95%

Rilonacept for Gout Flare Prevention in Patients Receiving Uric Acid-lowering Therapy: Results of RESURGE, a Phase III, International Safety Study

Sundy

Schumacher²,

Kivitz³

et al. 2014

J Rheumatol

View full text Add to dashboard Cite

show abstract

Section: Journal Of Rheumatologymentioning

confidence: 95%

Rilonacept for Gout Flare Prevention in Patients Receiving Uric Acid-lowering Therapy: Results of RESURGE, a Phase III, International Safety Study

Sundy

Schumacher²,

Kivitz³

et al. 2014

J Rheumatol

View full text Add to dashboard Cite

show abstract

“…When treated with anakinra, rilonacept or canakinumab, a rapid, sustained and remarkable reduction in pain as well as objective signs of reduced inflammation have been observed in Phase II and III trials 117–127 . Even gout of the lumbar spine responds to anakinra 128 .…”

Section: Clinical Trials Of Il-1-targeting Agentsmentioning

confidence: 99%

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

Dinarello

Simon²,

Meer³

2012

Nat Rev Drug Discov

1,556

1,305

View full text Add to dashboard Cite

Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory syndromes results in a rapid and sustained reduction in disease severity, including reversal of inflammation-mediated loss of sight, hearing and organ function. This approach can therefore be effective in treating common conditions such as post-infarction heart failure, and trials targeting a broad spectrum of new indications are underway. So far, three IL-1-targeted agents have been approved: the IL-1 receptor antagonist anakinra, the soluble decoy receptor rilonacept and the neutralizing monoclonal anti-IL-1β antibody canakinumab. In addition, a monoclonal antibody directed against the IL-1 receptor and a neutralizing anti-IL-1α antibody are in clinical trials.

show abstract

“…When treated with anakinra (Table 4), canakinumab (Table 5) or rilonacept (Table 6), a rapid, sustained and remarkable reduction in pain as well as objective signs of reduced inflammation have been observed [69–79]. The effect of IL-1 blockade appears to be superior to that of steroids and result in prolonged periods without flares.…”

Section: Arthritis and Joint Diseasesmentioning

confidence: 99%

Treating inflammation by blocking interleukin-1 in humans

Dinarello¹,

Meer²

2013

Seminars in Immunology

491

349

View full text Add to dashboard Cite

IL-1 is a master cytokine of local and systemic inflammation. With the availability of specific IL-1 targeting therapies, a broadening list of diseases has revealed the pathologic role of IL-1-mediated inflammation. Although IL-1, either IL-1α or IL-1β, was administered to patients in order to improve bone marrow function or increase host immune responses to cancer, these patients experienced unacceptable toxicity with fever, anorexia, myalgias, arthralgias, fatigue, gastrointestinal upset and sleep disturbances; frank hypotension occurred. Thus it was not unexpected that specific pharmacological blockade of IL-1 activity in inflammatory diseases would be beneficial. Monotherapy blocking IL-1 activity in a broad spectrum of inflammatory syndromes results in a rapid and sustained reduction in disease severity. In common conditions such as heart failure and gout arthritis, IL-1 blockade can be effective therapy. Three IL-1blockers have been approved: the IL-1 receptor antagonist, anakinra, blocks the IL-1 receptor and therefore reduces the activity of IL-1α and IL-1β. A soluble decoy receptor, rilonacept, and a neutralizing monoclonal anti-interleukin-1β antibody, canakinumab, are also approved. A monoclonal antibody directed against the IL-1 receptor and a neutralizing anti-IL-1α are in clinical trials. By specifically blocking IL-1, we have learned a great deal about the role of this cytokine in inflammation but equally important, reducing IL-1 activity has lifted the burden of disease for many patients.

show abstract

Case of anakinra as a steroid‐sparing agent for gout inflammation

Cited by 44 publications

References 6 publications

Rilonacept for Gout Flare Prevention in Patients Receiving Uric Acid-lowering Therapy: Results of RESURGE, a Phase III, International Safety Study

Rilonacept for Gout Flare Prevention in Patients Receiving Uric Acid-lowering Therapy: Results of RESURGE, a Phase III, International Safety Study

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

Treating inflammation by blocking interleukin-1 in humans

Contact Info

Product

Resources

About